Numerous antagonists targeting the TLR signaling cascade are identified as potential therapeutic targets for SLE29, including TLR7 antagonists which could inhibit Th1-type cytokines release, such as IFN-α and modulate the imbalance of Th1/Th2 cytokines environment in SLE patients. Here, IFNA1 is linked to systemic lupus erythematosus.